There are 2185 resources available
440O - First in human study of the mRNA-based cancer vaccine CVGBM in patients (pts) with newly diagnosed and surgically resected MGMT-unmethylated glioblastoma (GBM): First results from the dose escalation phase
Presenter: Ghazaleh Tabatabai
Session: Proffered paper session: CNS tumours
Resources:
Abstract
799MO - The primary results from a randomized double-blind phase II study of rovadicitinib versus hydroxyurea in patients with myelofibrosis
Presenter: Ling Pan
Session: Mini oral session 1: Haematological malignancies
Resources:
Abstract
LBA48 - CCTG BR.31: A global, double-blind placebo-controlled, randomized phase III study of adjuvant durvalumab in completely resected non-small cell lung cancer (NSCLC)
Presenter: Glenwood Goss
Session: Proffered Paper session: Non-metastatic NSCLC
Resources:
Abstract
441O - A phase I clinical trial on the intracranial administration of autologous CD1c(BDCA-1)+ /CD141(BDCA-3)+ myeloid dendritic cells (myDC) in combination with ipilimumab (IPI) and nivolumab (NIVO) in patients with recurrent high-grade glioma (rHGG)
Presenter: Bart Neyns
Session: Proffered paper session: CNS tumours
Resources:
Abstract
800MO - First report of BCL-2 inhibitor TQB3909 in pts with relapsed or refractory non-Hodgkin lymphoma (NHL) and acute myeloid leukemia (AML): Data from a phase I study
Presenter: Junyuan Qi
Session: Mini oral session 1: Haematological malignancies
Resources:
Abstract
LBA74 - Final analysis of the phase III LITESPARK-005 study of belzutifan versus everolimus in participants (pts) with previously treated advanced clear cell renal cell carcinoma (ccRCC)
Presenter: Brian Rini
Session: Proffered paper session 1: GU tumours, non-prostate
Resources:
Abstract
442O - A phase I clinical trial of intrathecal injection of allogeneic CAR-γδT cells targeting B7H3 for the treatment of patients with recurrent glioblastoma
Presenter: Yulun Huang
Session: Proffered paper session: CNS tumours
Resources:
Abstract
801MO - Efficacy and safety of a phase II study: Timdarpacept (IMM01) combined with azacitidine (AZA) as the first-line treatment in adults with chronic myelomonocytic leukemia (CMML)
Presenter: Liya Ma
Session: Mini oral session 1: Haematological malignancies
Resources:
Abstract
LBA75 - Prospective randomised phase-II trial of ipilimumab/nivolumab versus standard of care in non-clear cell renal cell cancer: Results of the SUNNIFORECAST trial
Presenter: Lothar Bergmann
Session: Proffered paper session 1: GU tumours, non-prostate
Resources:
Abstract
LBA81 - Durvalumab (D) as consolidation therapy in limited-stage SCLC (LS-SCLC): Outcomes by prior concurrent chemoradiotherapy (cCRT) regimen and prophylactic cranial irradiation (PCI) use in the ADRIATIC trial
Presenter: Suresh Senan
Session: Proffered Paper session: Non-metastatic NSCLC
Resources:
Abstract